Regeneron Pharmaceuticals, Inc. $REGN Stock Bought by Lmcg Investments LLC

Lmcg Investments LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,703 shares of the biopharmaceutical company’s stock after buying an additional 866 shares during the period. Regeneron Pharmaceuticals comprises 1.5% of Lmcg Investments LLC’s investment portfolio, making the stock its 11th largest position. Lmcg Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $28,589,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $5,682,636,000. State Street Corp boosted its stake in shares of Regeneron Pharmaceuticals by 3.6% in the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after purchasing an additional 170,210 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Regeneron Pharmaceuticals by 8.5% during the 2nd quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock valued at $805,023,000 after purchasing an additional 101,469 shares during the last quarter. Amundi raised its position in Regeneron Pharmaceuticals by 0.4% in the 2nd quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock worth $631,983,000 after purchasing an additional 3,742 shares during the period. Finally, Legal & General Group Plc purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $473,872,000. Institutional investors own 83.31% of the company’s stock.

Insider Activity

In related news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Down 0.2%

Shares of NASDAQ REGN opened at $805.67 on Thursday. The firm’s fifty day moving average is $791.56 and its 200 day moving average is $722.18. Regeneron Pharmaceuticals, Inc. has a 52 week low of $572.75 and a 52 week high of $859.34. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The company has a market cap of $82.95 billion, a price-to-earnings ratio of 19.91, a PEG ratio of 1.37 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $12.81 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 48.87 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on REGN. Sanford C. Bernstein boosted their price target on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a “market perform” rating in a research note on Friday, August 14th. Cantor Fitzgerald upped their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Leerink Partners lifted their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Finally, Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $846.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.